|
|
|
|
|
CleocinThe change in valuation allowances in the year to December 31, 2006 included a reversal in the fourth quarter of 0 million of valuation allowances in place at January 1, 2006, of which million related to the UK, million to the US and million to certain European affiliates. The Company recognized the reversal of these valuation allowances primarily following the implementation of tax planning strategies during the fourth quarter of the year to December 31, 2006 and revisions to projections of future earnings in certain European jurisdictions, which led the Company's management to determine that it was now more likely than not that the relevant tax loss carry-forwards would be realizable. The valuation allowances were not reversed until the fourth quarter of 2006 as the predominant tax planning strategies which triggered the recognition of the reversals were either not in place or did not provide a prudent and feasible source of taxable income until the fourth quarter. Prior to the reversal of these valuation allowances, the Company had determined that it was more likely than not that the related deferred tax assets would not be realized, primarily as a result of insufficient future taxable income being available to overcome cumulative losses. The effect of this reversal is included in the increase in net deferred tax assets to 1.0 million at December 31, 2006 2005: 6.2 million ; . Realization of deferred tax assets is dependent upon generating sufficient taxable income to utilize such assets. Although realization of these assets is not assured, it is more likely than not that the amount recognized will be realized. Change in provisions for uncertain tax positions The Company adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, "FIN 48" ; on January 1, 2007. There was no cumulative effect adjustment to the opening balance of retained earnings arising as a result of the adoption of FIN 48. The balance of the provision for unrecognised tax benefit, at January 1, 2007 totalled 4.4 million. The Company files income tax returns in the UK, the US both federal and state ; and various other jurisdictions see footnote 1 ; to the table above for major jurisdictions ; . With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 1999. Tax authorities in various jurisdictions are in the process of auditing the Company's tax returns for fiscal periods from 1999; these tax audits cover a range of issues, including transfer pricing, potential restrictions on the utilization of net operating losses, potential taxation of overseas dividends and controlled foreign companies rules. During the year to December 31, 2007 changes in the Company's provision for unrecognized tax benefits reduced the effective rate by 2.7%, or .1 million, which relates to .1 million of movements in the unrecognized tax benefits and .0 million for interest and penalties. The increase in the provision for unrecognized tax benefits of .1 million is due to additional provisions of .4 million recognised in relation to potential transfer pricing adjustments, the deductibility of expenses and availability of certain tax reliefs, which is partially offset by a reduction in the provision as a result of expiration of the statute of limitations of .3 million. The Company considers it reasonably possible that the total amount of unrecognized tax benefits recorded at December 31, 2007 could decrease by approximately million in the next twelve months, due to the completion of various tax audits in several jurisdictions. While tax audits remain open, the Company also considers it reasonably possible that new issues may be raised by tax authorities resulting in increases to the balance of unrecognised tax benefits, however an estimate of such an increase cannot be made. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows. Store at controlled room temperature 20 to 25C 68 to 77F ; [see USP]. CLEOCIN PHOSPHATE IV Solution in Galaxy plastic containers is a sterile solution of clindamycin phosphate with 5% dextrose. The single dose Galaxy plastic containers are available as follows: 24-300 mg 50 ml containers NDC 0009-3381-02.
Arthritis, Abnormalities of Cartilage in Arthritis in the Adult, Bacterial Suppurative ; . Patrick J. Kelly, Willians. Cleocin t gel for acne
Other events occurring in 1% of the clindamycin vaginal cream 2% groups include: Urogenital system: vaginal discharge, metrorrhagia, urinary tract infection, endometriosis, menstrual disorder, vaginitis vaginal infection, and vaginal pain. Body as a whole: localized abdominal pain, generalized abdominal pain, abdominal cramps, halitosis, headache, bacterial infection, inflammatory swelling, allergic reaction, and fungal infection. Digestive system: nausea, vomiting, constipation, dyspepsia, flatulence, diarrhea, and gastrointestinal disorder. Endocrine system: hyperthyroidism. Central nervous system: dizziness and vertigo. Respiratory system: epistaxis. Skin: pruritus non-application site ; , moniliasis, rash, maculopapular rash, erythema, and urticaria. Special senses: taste perversion. Pregnant Women: In a clinical trial involving pregnant women during the second trimester, 1.7% of 180 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 22.8% of pregnant patients. Events occurring in 1% of patients receiving either clindamycin phosphate vaginal cream 2% or placebo are shown in Table 2. TABLE 2 - Events Occurring in 1% of Pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2% or Placebo CLEOCIN Placebo Vaginal Cream Event 7 DAY 7 Day n 180 n 184 Urogenital Vaginal moniliasis 13.3 7.1 Vulvovaginal disorder 6.7 7.1 Abnormal labor 1.1 0.5 Body as a Whole Fungal infection 1.7 0. Skin Pruritus, non-application site 1.1 0 and minocin. BECONASE AQ AEROSOL, SPRAY, GM ; BENZAMYCIN GEL GM ; BETAGAN DROPS BIAXIN SUSPENSION, RECONSTITUTED, ORAL ml ; BIAXIN TABLET BIAXIN XL TABLET, SUSTAINED RELEASE 24HR BLEPH-10 DROPS BREVICON TABLET CADUET TABLET CAPITAL W-CODEINE SUSPENSION, ORAL FINAL DOSE FOR CEDAX CAPSULE HARD, SOFT, ETC. ; CEFTIN TABLET CEFZIL SUSPENSION, RECONSTITUTED, ORAL ml ; CEFZIL TABLET CELEXA SOLUTION, ORAL CELEXA TABLET CILOXAN DROPS CIPRO HC SUSPENSION, DROPS FINAL DOSAGE FORM ; ml ; CIPRO TABLET CIPRO XR TABLET, SUSTAINED RELEASE 24HR CLARINEX-D 24 HOUR TABLET, MULTIPHASIC RELEASE 24H CLEOCIN HCL CAPSULE HARD, SOFT, ETC. ; CLEOCIN T GEL GM ; CLEOCIN T LOTION ml ; CLEOCIN T SOLUTION, NON-ORAL CLEOCIN T SWAB, MEDICATED CLINDETS SWAB, MEDICATED COLY-MYCIN S SUSPENSION, DROPS FINAL DOSAGE FORM ; COMBIPATCH PATCH, TRANSDERMAL SEMIWEEKLY COMBUNOX TABLET CRESTOR TABLET DARVOCET -N 100 TABLET DARVOCET -N 50 TABLET DDAVP AEROSOL, SPRAY W PUMP ml ; DECLOMYCIN TABLET DEMULEN 1 50-21 TABLET DESOGEN TABLET DURAGESIC PATCH, TRANSDERMAL 72 HOURS DYNACIN CAPSULE HARD, SOFT, ETC. ; E.E.S. 200 SUSPENSION, RECONSTITUTED, ORAL ml ; ELESTAT DROPS ELOCON OINTMENT GM ; EMADINE DROPS ERYPED 200 SUSPENSION, RECONSTITUTED, ORAL ml ; ESTRACE CREAM WITH APPLICATOR EXELDERM CREAM GRAMS. Alike broke his heart again. For Jill, it was finding the Christmas decorations while clearing her flat. Hazel's door wreath was over the top, bright and musical. It amused Jill at first playing and irritated ever after. Of course, Hazel loved it and finding it in September when she cleared the flat was too much for Jill. For me it's a china donkey. It's a moneybox, ugly beyond words but practical. Hazel gave it to me hold the loose change our visitors in Cyprus don't carry home. Eventually we're to give the cash to the donkey sanctuary. It just epitomizes the cheeky, practical and compassionate mixture that was Hazel. Her brother and his fianc went to the bar in Paphos where the photo that we used for her life's celebration was taken, it is the one used in this article. They drank Bacardi Breezers and raised a toast. Her time in the sun is over but we celebrate her life and ethionamide. The evidence collection exam is done by a registered nurse, nurse practitioner, physician assistant or physician currently licensed in Oregon. The preferred examiner is one who is trained and certified as a Sexual Assault Forensic Examiner. Cleocin suppositoryPediazole Add Ciloxan to the Quinolones PNPseudomonal Risk SIP-Colon or Hysterectomy -lactam Allergy ; table Add Adoxa, DoxyCaps and Periostat to the Tetracyclines table Add Genticin and G-Mycin to the Aminoglycosides Pseudomonal Risk ; table Add Clelcin HCL and Cle9cin Phosphate to the Clindamycin table Add Lyphocin and Vancocin HCL to the Glycopeptides table Add Cefoxitin to the Colon Parenteral Antibiotics I table and delete Cefozitin and the duplicated Cefotetan from the same table. Add EYRC, Erythomycin Sulfisoxazole and Pediamycin to the Colon Oral Antibiotics II table Add Lyphocin and Vancocin HCL to the CABG, Cardiac or Vascular, Hip Knee Arthoplasty table Add Clepcin HCL and Cleocin Phosphate to the CABG, Cardiac or Vascular, Hip Knee Arthroplasty, -lactam allergic Colon and Hysterectomy Antibiotics table Add the following medications to the All Surgeries Antibiotic Fluroquinolone table: Alatrofloxacin Mesylate Avelox Ciloxan Ciprofloxacin Hydrochloride Floxin Moxifloxacin Hydrochloride TEC-PAQ Trovafloxacin Mesylate Trovafloxacin Alatrofloxacin Trovan Add G-Mycin to the Colon, Hysterectomy -lactam Allergy - Antibiotics table Add title to the top of the page "LVSD Notes Table cont.", page Appendix H-5. Changes have been made in the "Definitions of Valid Format for Patient Identifiers" on page Appendix 1-2. Delete the last 2 bullets under "If First Character is Numeric" and the last bullet under "If the First Character is Alpha. COMBIVENT 14 COMBIVIR 10 COMTAN 23 COMVAX 34 bupropion hcl smoking deterrent ; 21 chloramphenicol sodium succinate 8 CONCERTA 22 bupropion hcl 21 chlorhexidine gluconate mouthCOPAXONE 38 buspirone hcl 23 throat ; 27 CORDRAN TAPE 36 BYETTA 32 chloroquine phosphate 11 CORDRAN 36 chlorothiazide 25 cortisone acetate 30 C chlorpromazine hcl 22 COSMEGEN 12 cabergoline 38 chlorpropamide 32 COSOPT 28 calcitonin salmon ; 33 chlorthalidone 25 COUMADIN 15 calcitriol 38 chlorzoxazone 15 CREON 10 29 CAMPATH 12 cholestyramine light 17 CREON 20 29 CAMPTOSAR 12 cholestyramine 17 CREON 5 29 CANASA 30 chorionic gonadotropin 32 CRESTOR 17 CANCIDAS 9 ciclopirox olamine 35 CRIXIVAN 10 CAPEX 36 cilostazol 16 cromolyn sodium ophth ; 26 captopril & hydrochlorothiazide 19 CILOXAN 26 cromolyn sodium 26 captopril 19 cimetidine hcl 29 CUBICIN 9 CARAFATE 29 cimetidine 29 CUPRIMINE 30 carbamazepine 21 CIPRO I.V.-IN D5W 8 CURITY GAUZE PADS 2"X2" 40 CARBATROL 21 CIPRO 8 CVS GAUZE PAD STERILE 2"X 40 carbidopa-levodopa 23 CIPRODEX 27 cyclobenzaprine hcl 15 carboplatin 12 ciprofloxacin hcl ophth ; 26 cyclophosphamide 12 CARIMUNE NF 34 ciprofloxacin hcl 8 cyclosporine modified for carisoprodol w aspirin 15 ciprofloxacin 8 microemulsion ; 38 carisoprodol 15 cisplatin 12 cyclosporine 38 CASODEX 12 citalopram hydrobromide 21 CYKLOKAPRON 16 CATAPRES-TTS 2 17 cladribine 12 CYMBALTA 21 CATAPRES-TTS-1 17 clemastine fumarate 7 cyproheptadine hcl 7 CATAPRES-TTS-2 17 CLEOCIN 35 CYSTADANE 38 CATAPRES-TTS-3 17 CLEOCIN 9 CYSTAGON 38 CEENU 12 clindamycin hcl 9 cytarabine 12 cefaclor 7 clindamycin phosphate topical ; 35 CYTOMEL 33 cefadroxil 7 clindamycin phosphate vaginal 35 D cefazolin sodium 7 clindamycin phosphate 9 cefdinir 7 dacarbazine 12 and floxin. Issue which was almost all from Canada to having articles and reports from around the world, even including the World Health Organization. A proposal has been submitted to NATO to sponsor a Workshop in Turkey in 2005. He told of discussions with the enthusiastic delegates from China who will establish a section, host a meeting in 2004 and provide members for the publications editorial boards. He encouraged involvement in the Journal, Experimental & Clinical Cardiology. Buoyed by the continuing growth of the Public Forum, held for the third time in Winnipeg in May, 2003, he encouraged the planning of such initiatives around the world contact him for assistance. Dr. Ostadal offered some learned suggestions for the Academy: 1. Membership must be encouraged rules should be established internationally but strategies developed by sections. 2. A formal link should be set with ISHR. An offi. Side effects of cleocinMixed penning usually caused an immediate and high level of aggressive butting and mounting activity between the experimental pair and the established group. This activity continued throughout the mixing period, although at a somewhat lower level as the social hierarchy was established and the animals became exhausted. Being stall-fed and unused to exercise, the experimental animals showed the expected consequences of physical activity, including increased heart and respiration rates, sweating and high body temperature. The animals somtimes showed signs of stiffness or muscle ache for 1 or 2 after stress. Muscle glycogen breakdown was continuous during the period of stress in both the untreated and the propranolol-treated groups. The rate in the untreated bulls was 23.7 amol g for the first hour and then decreased to 7.7 amol'g -1" h -l. Similar rates of glycogen breakdown were observed in equine M. gluteus medius at slow trotting speed 21 amol'g-l'h -1 for 3 h reducing to 8 l -l"h -1 for the final hour of exercise; Lindholm et al., 1974 ; . The high initial rate of glycogen breakdown in the untreated bulls may be associated with a higher intensity of stress during the early part of the mixing period. Kenny and Tarrant 1982 ; reported a significantly higher level of agonistic interactions between young Friesian bulls during the early part of a 4 mixing period. Furthermore, oxidative metabolism may become a more important source of muscle energy with time, as the organism adjusts to the stressor. It is possible to modify the rate of glycogen breakdown during exercise by altering the. 6. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992; 17: 1658. Ede M. A double-blind, comparative study of benzoyl peroxide, benzoyl peroxide-chlorhydroxyquinoline, benzoyl and placebo lotions in acne. Curr Ther Res Clin Exp 1973; 15: 6249. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986; 25: 6647. Pedace FJ, Stoughton R. Topical retinoic acid in acne vulgaris. Br J Dermatol 1971; 84: 4659. Christiansen JV, Gadborg E, Ludvigsen K, et al. Topical tretinoin, vitamin A acid Airol ; in acne vulgaris. A controlled clinical trial. Dermatologica 1974; 148: 829. Berson DS, Shalita AR. The treatment of acne: the role of combination therapies. J Acad Dermatol 1995; 32: 53141. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Acad Dermatol 1996; 34: 4825. Cunliffe W, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Acad Dermatol 1997; 36: S12634. 14. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998; 139: S3440. 15. Clucas A, Verschoore M, Sorba V, et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Acad Dermatol 1997; 36: S1168. 16. Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl 1989; 143: 404. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl 1989; 143: 359. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double blind, vehicle-controlled study. Cutis 1999; 63: 34953. Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol 1981; 117: 4825. Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL. A comparison of Cleocin T Solution, Cleocin T Gel, and placebo in the treatment of acne vulgaris. Cutis 1988; 42: 2457. Pochi PE, Bagatell FK, Ellis CN, et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41: 1326. Lesher JL Jr, Chalker DK, Smith JG Jr, et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Acad Dermatol 1985; 12: 52631. Dobson RL, Belknap BS. Topical erythromycin solution in acne. Results of a multiclinic trial. J Acad Dermatol 1980; 3: 47882. Leyden JJ, Shalita AR, Saatjian GD, Sefton J. Erythromycin 2% gel in comparison with clindamycin and trimox and Cleocin online. Generic cleocin clindamycin ; 150mg generic cleocin clindamycin ; 300mg show cleocin clindamycin ; full description what is the most important information i should know about cleocin. REVERSE TRANSCRIPTASE INHIBITORS RTIs ; abacavir sulfate Ziagen ; didanosine ddI, dideoxyinosine, Videx, Videx EC ; emtricitabine Emtriva, FTC ; lamivudine 3TC, Epivir ; stavudine d4T, Zerit ; tenofovir DF Viread ; zidovudine AZT, azidothymidine, Retrovir ; * Combivir Epivir and Retrovir Combination ; * Truvada Emtriva and Viread combination ; * Epzicom Epivir and Ziagen Combination ; * Trizivir Epivir, Retrovir and Ziagen Combination ; * Atripla efavirenz emtricitabine tenofovir ; PROTEASE INHIBITORS PIs ; amprenavir Agenerase ; , solution only atazanavir Reyataz ; darunavir Prezista ; fosamprenavir calcium Lexiva ; indinavir Crixivan ; lopinavir ritonavir Kaletra ; nelfinavir mesylate Viracept ; ritonavir Norvir ; saquinavir mesylate Invirase ; tipranovir Aptivus ; NON-NUCLEOSIDE RTIs ; delavirdine Rescriptor ; efavirenz Sustiva ; etravirine Intelence ; nevirapine Viramune ; ENTRY INHIBITOR Maraviroc Selzentry ; INTEGRASE INHIBITOR Raltegravir Isentress ; CATEGORY II TREATMENT and PROPHYLAXIS of PCP atovaquone Mepron ; * clindamycin HCl Cleocin Hcl ; dapsone pentamidine isethionate NebuPent, Pentam 300 ; primaquine phosphate trimethoprim TMP, Proloprim, Trimpex ; sulfamethoxazole trimethoprim SMZ TMP, Bactrim, ; ANTI-DIARRHEA or WASTING SYNDROME dronabinol Marinol ; megestrol acetate Megace ; Lomotil Imodium TOXOPLASMOSIS: * azithromycin dihydrate Zithromax ; clindamycin phosphate Cleocin Phosphate ; clindamycin palmitate Cleocin pediatric granules ; leucovorin calcium folinic acid ; pyrimethamine Daraprim ; sulfamethoxazole Gantanol, Urobak ; sulfadiazine CATEGORY IV Other ; Aldara imiquimod cream ; interferon alfa-2b Intron A ; danazol Danocrine ; multivitamins-minerals metronidazole, oral gabapentin Neurontin ; tinidazole Tindamax ; clobetasol propionate cream podofilox Condylox ; testosterone enanthate, I.M only LIPID REGULATING ezetimibe Zetia ; atorvastatin Lipitor ; pravastatin Pravachol ; fenofibrate Tricor ; CATEGORY V - REQUIRING PRIOR APPROVAL Fuzeon enfurvirtide requires an additional application; limited to a cap of 100 clients. Valcyte valganciclovir hydrochloride ; oral only; Cap is limited to 35 clients concurrently. * Duplicate drug appears more than once. * Indicates a fixed combination of two-drugs that are considered two drugs in the 5 + drug limit; * Trizivir and Atripla are a three-drug combination and are considered three drugs and zithromax! Judged to have moderate tardive dyskinesia, compared with five patients in the control group. The mean total rating of tardive dyskinesia in the patients who had died was 3.2. Coinciding with the appearance in Atlanta of the anti-abortion caravan see related story ; , Operation Save America formerly Operation Rescue National ; leader Philip "Flip" Benham of Dallas, Texas, was arrested outside an Atlanta abortion clinic and charged with criminal trespass, disorderly conduct, and obstruction. Benham allegedly ignored the repeated warnings by law enforcement officers and was arrested. A day earlier, Benham had entered the same clinic, seated himself in the waiting room, and announced he would conduct "spiritual counseling"; he left when asked to do so officials. [Source: Operation Save America]. Activation steps: Pre2 formation RarelativeRa Ra + Rc Re, triangles, frame C ; , MzIIa formation RcrelativeRc Ra + Rc circles, frame D ; , and channeling RerelativeRe Ra + Rc squares, frame E ; . The relative rates of channeling without factor Va is also reproduced cross-filled symbols ; from 2 ; The x symbols on ordinates mark the relative rates in presence of factor Va and absence of membrane taken from 1 ; . FIGURE 5: Best fits of simulations to observed prothrombin proteolysis data at 20, 50, 200, M PS DOPC LUV concentrations. Left panel: Prothrombin 0.5 M ; proteolysis catalyzed by Factor Xa 2.5 nM ; in the presence of 5 mM CaCl2, factor Va 30 nM ; , and of different concentrations of PS DOPC 25 75 ; at 37C. Formation of thrombin plus MzIIa circles ; and appearance of MzIIa squares ; during prothrombin proteolysis was followed by generation of amidolytic activity towards the synthetic substrate S2238 at all lipid concentrations and by SDS-PAGE open symbols ; at 200 M see Methods ; . Pre2 could not be detected by SDS-PAGE open triangles ; . All experimental curves were fitted simultaneously using the SigmaPlot simulation program to obtain estimates for the rate constants Ra, Rc and Re channeling ; . Simulated curves were calculated using best. Cleocin 2 antibioticCleocin capsuleA regular exercise program that involves some stretching and weight bearing short of becoming exhausted ; is beneficial because, as motor function becomes more impaired, an exercise program or physical therapy may help maintain or reestablish physical conditioning. Recently, there has been much interest in the public health ramifications of the sexual transmission of HAART-resistant virus. This year there have been conflicting reports claiming there has either been a rise or a decline in the number of people who are acquiring resistant strains of HIV sexually. According to a recent US study25, resistance to at least one antiretroviral increased from 3.4% in the period 1995-1998 to 12.4% in the period 1999-2000, and multi-drug resistance increased from 1.1% to 6.2% in the same timeframe. The picture is not the same everywhere that HAART is in use, however. A group of Spanish researchers recently found that prevalence of antiretroviral drug resistance mutations fell during a similar period26. Explaining the differences in these findings, Dr Taylor states: "The study populations are extremely diverse, as are the definitions of newly-infected individuals. The bottom line is that drug resistant HIV can be transmitted." Complicating matters is the fact that resistance in the blood and semen are not always concordant27. "Some studies have found that resistance develops first in the genital tract, and others that resistance can occur in the blood but be absent in the genital tract, " says Dr Taylor. "Most of the cases that we have investigated so far have identical mutations in blood and semen30, but more data are required. Not provided for dre-detecte d cancers.
Foods cooked at high temperatures, cause a significant dysfunction in blood vessel dilation that can lead to heart disease. |